Last reviewed · How we verify
NCT05781256: CABER-NET
Novel BP Monitoring Methods to Study the Association Between Sleep BP Patterns and BP Values in Daily Life
trial in Ambulatory Blood Pressure Monitoring in 173 participants. Completed in 27 April 2024.
31 December 2023
Quick facts
| Lead sponsor | Istituto Auxologico Italiano |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 173 |
| Start date | 1 June 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 27 April 2024 |
| Sites | 1 location across Italy |
Conditions studied
- Ambulatory Blood Pressure Monitoring — all drugs for Ambulatory Blood Pressure Monitoring →
- Home Blood Pressure Monitoring — all drugs for Home Blood Pressure Monitoring →
- Blood Pressure Determination — all drugs for Blood Pressure Determination →
- Arterial Hypertension — all drugs for Arterial Hypertension →
Sponsor
Istituto Auxologico Italiano — full company profile →
Who can join
19 and older, any sex, with Ambulatory Blood Pressure Monitoring or Home Blood Pressure Monitoring. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Out-of-office blood pressure (BP) measurement by means of ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM) is recommended for the diagnosis and management of hypertension in the latest guidelines. Ambulatory BP values are more strongly associated with target organ damage and cardiovascular (CVD) events than office values. In particular, nocturnal blood pressure level and reduction of BP during the night (dipping) have been recognised as predictors of cardiovascular complications. However, in current clinical practice, these parameters are derived from ABPM. HBPM represents an inexpensive alternative to ABPM, is preferred by patients and provides a more realistic assessment of BP during an individual's daily life. However, until recently, HBPM did not offer the possibility to measure nocturnal BP or dipping. The development and validation of new BP devices, such as the NightView (OMRON Healthcare, HEM9601T-E3) could overcome this limitation, offering the possibility of home night-time BP measurements with minimal sleep disturbance. On the other hand the use of wearable devices such as HeartGuide (OMRON Healthcare, HEM-6411T-MAE) could provide BP values in daily life conditions. Compared with conventional HBP, typically measured in resting conditions at home, values obtained with wearable devices might be closer to daytime ABP values. Combining nocturnal HBP, with daytime BP from wearable device could therefore allow the estimation of dipping status comparable with that provided by ABPM. In order to compare HBP-derived dipping estimate with the gold standard ABPM-derived value, it is aimed to enrol patients with hypertension, assess their blood pressure profile with ABPM and provide them with both NightView and HeartGuide devices for 7 days. Then diurnal and nocturnal BP and dipping derived from standard 24-hour ABPM will be compared and the combination of NightView/HeartGuide in order to understand whether the latter can offer a reliable assessment of 24h BP pattern. For a better phenotypization of nocturnal BP and dipping status the following determinants of nocturnal BP and dipping status will be also investigated: sleep quality, sleep duration, the presence of sleep disorders, salt consumption, catecholamine phenotype. This study will offer the unique opportunity to understand whether such new HBP devices can be offered in alternative to ABPM in the assessment of 24h BP profile in patients with hypertension.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05781256
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Istituto Auxologico Italiano trials
Trials by the same sponsor.
- NCT07384962 — ORION Study: Mesh Position and Risk During Subsequent Minimally Invasive Abdominal Surgery · not yet recruiting
- NCT07358832 — Neuromodulation Through Multisensory Stimulation for Visual Field Deficits in the Subacute Stage of Disease · NA · recruiting
- NCT07302321 — Needs of ALS Patients With C9orf72 Mutation and Their Caregivers · recruiting
- NCT07162740 — Implantable Loop Recorder and Cardioneuroblation · not yet recruiting
- NCT07312240 — LONgitudinal and Integrated Evaluation of Biomarkers in reLation to phenotYpe in ALS · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05781256 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituto Auxologico Italiano
- Last refreshed: 24 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05781256.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing